Compare BOSC & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | ELUT |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 25.2M |
| IPO Year | 1996 | 2020 |
| Metric | BOSC | ELUT |
|---|---|---|
| Price | $4.27 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 132.7K | ★ 228.1K |
| Earning Date | 11-25-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $48,333,000.00 | $21,746,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.27 | ★ N/A |
| Revenue Growth | 19.49 | ★ 24.08 |
| 52 Week Low | $3.14 | $0.58 |
| 52 Week High | $6.72 | $4.84 |
| Indicator | BOSC | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 39.88 |
| Support Level | $4.36 | $0.66 |
| Resistance Level | $4.96 | $0.72 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 18.82 | 39.47 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.